Blackberry Empire – Lifestyle
Author:
Kestrel Therapeutics Inc.
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
April 28, 2026